ArticleScientific reports2026
Association between ABO blood groups and clinical manifestations and outcomes of COVID-19: a retrospective cross-sectional study in southeast Iran.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood groups significantly influence individuals' immune responses and the severity of diseases. This study examined the association between ABO blood groups and clinical features, comorbidities, and outcomes in COVID-19 patients in southeast Iran. This retrospective cross-sectional study included 894 RT-PCR-confirmed COVID-19 patients admitted to two referral hospitals in southeast Iran (April-September 2020). Medical records were reviewed for demographic data, ABO blood groups, clinical features, comorbidities, and outcomes. Disease severity was classified using NIH criteria. Chi-square, Kruskal-Wallis, and multivariable logistic regression (adjusted for age, sex, and comorbidities) were used for analysis. The mean age was 37.36 ± 14.63 years, and 53.1% were female. The mean number of symptoms varied significantly across ABO blood groups (P = 0.014), with group AB showing the lowest values. Hospitalization rates also differed (P = 0.003), being highest in group O. Significant associations were observed between blood groups and fever/chills, cough, rhinorrhea, headache, and gastrointestinal symptoms (all P < 0.05). Comorbidities were more frequent in group O (P = 0.005), particularly cardiovascular disease (P = 0.037). Blood group AB remained independently associated with fewer symptoms after adjustment (aOR = 0.68, 95% CI 0.47-0.98). ABO blood groups were associated with clinical presentation and comorbidities in COVID-19 patients. Blood group O showed higher rates of comorbidities and hospitalization, while blood group AB had a milder symptom profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.